Bio-Techne stock slides 5.01% in favourable market session
Updated
Updated · MarketWatch · May 8
Bio-Techne stock slides 5.01% in favourable market session
13 articles · Updated · MarketWatch · May 8
Shares closed at $48.36 as the S&P 500 rose 0.84% to 7,398.93 and the Dow Jones Industrial Average added 0.02% to 49,609.16.
The stock finished 32.98% below its 52-week high of $72.16, reached on 22 January, and lagged Amgen, while Charles River Laboratories and BioMarin also declined.
Trading volume reached 3.8 million shares, well above its 50-day average of 2.4 million, indicating heavier-than-usual investor activity during the sell-off.
After its stock plunge, can Bio-Techne’s booming spatial biology unit prove its premium valuation is still justified?
Beyond the earnings miss, do new US pharma tariffs pose a hidden threat to Bio-Techne's long-term growth?
Is selling its diagnostics unit a savvy pivot or a short-sighted move to appease investors amid market headwinds?